{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-002117","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.845668+00:00","generated_at":"2026-05-25T13:50:12.253240+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Coherus supplements proxy for UDENYCA sale; discloses JPMorgan valuation & cash flow projections","bullets":["Four shareholder complaints filed in NYC Supreme Court alleging proxy deficiencies; company denies merit.","Voluntarily adds JPMorgan's selected transaction analysis: implied consideration ~$530M (base plus risk-adjusted earnout).","Discloses UDENYCA unlevered free cash flow: $51M in 2025E, rising to $105M by 2029E, with revenue $186M in 2025E.","Special meeting to approve sale to Intas Pharmaceuticals remains scheduled for March 11, 2025.","Company believes no supplemental disclosures are legally required but provides them to avoid litigation delay."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-002117","json":"https://secwatch.observer/filing/0001558370-25-002117.json","markdown":"https://secwatch.observer/filing/0001558370-25-002117.md","text":"https://secwatch.observer/filing/0001558370-25-002117.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000155837025002117/0001558370-25-002117-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000155837025002117/chrs-20250304x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T13:50:12.253240+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}